Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCONTIN vs DRONABINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.
Partial agonist at cannabinoid receptors CB1 and CB2; mimics endogenous cannabinoids, inhibiting adenylate cyclase and modulating neurotransmitter release (e.g., GABA, glutamate).
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,Off-label: Treatment of opioid dependence (as part of substitution therapy)
Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetics,Anorexia associated with weight loss in patients with AIDS
10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.
2.5-10 mg orally twice daily, titrated to effect; maximum 15 mg per day in divided doses.
4.5-5.0 hours (immediate-release); controlled-release OXYCONTIN has an apparent half-life of 4.5-8.7 hours. Terminal half-life is ~3.5-4 hours for immediate-release, reflecting context-sensitive elimination.
Terminal elimination half-life is approximately 25–36 hours in chronic users due to extensive tissue distribution and slow release from fat stores; in naive users, half-life is shorter, around 20–30 hours. The prolonged half-life contributes to accumulation with repeated dosing.
Oxycodone is metabolized primarily via CYP3A4 to noroxycodone (major metabolite) and via CYP2D6 to oxymorphone (minor metabolite). Both metabolites are active, with oxymorphone having higher potency. Oxycodone and its metabolites are conjugated and excreted in urine.
Hepatic via CYP2C9 and CYP3A4; major metabolite 11-hydroxy-dronabinol (active); further oxidation to 11-nor-9-carboxy-dronabinol.
Primarily renal (90% as metabolites, 10% unchanged). Also biliary/fecal (10%).
Primarily hepatic metabolism followed by biliary and fecal excretion. Approximately 65% eliminated in feces and 35% in urine, mostly as metabolites. Less than 5% of unchanged drug is excreted in urine.
38-45%, primarily bound to albumin.
Highly protein-bound: >95% bound primarily to albumin and, to a lesser extent, lipoproteins.
2.6-3.0 L/kg. Extensive tissue distribution, high Vd indicates penetration into peripheral tissues.
Extremely large, estimated at 10–30 L/kg due to high lipophilicity and extensive tissue uptake, particularly into adipose tissue and brain. This accounts for the slow elimination and prolonged action.
Oral immediate-release: 60-87% (first-pass metabolism). Oral extended-release (Oxy Contin): 60-87% (similar). Intravenous: 100%.
Oral bioavailability is low and variable, approximately 10–20% due to extensive first-pass hepatic metabolism. There is significant interindividual variability based on metabolism and formulation.
Cr Cl 30-60 m L/min: reduce dose by 25%; Cr Cl <30 m L/min: reduce dose by 50% and administer every 12 hours; hemodialysis: avoid use.
No dosage adjustment necessary for GFR >30 m L/min; insufficient data for GFR <30 m L/min, use with caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce starting dose to 1.25-2.5 mg twice daily and titrate cautiously; Child-Pugh C: avoid use.
Not approved for pediatric patients <18 years; for children ≥11 years (opioid-tolerant): 0.2 mg/kg orally every 12 hours, titrate; maximum single dose 10 mg.
Not recommended for use in children under 18 years due to lack of safety and efficacy data.
Initiate at 5 mg orally every 12 hours; titrate cautiously; monitor for respiratory depression and constipation.
Initiate at 1.25-2.5 mg twice daily; monitor for CNS effects and falls; titrate slowly.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
None
Addiction, abuse, and misuse: Oxy Contin exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors or conditions.,Life-threatening respiratory depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor for respiratory depression, especially during initiation of therapy or following a dose increase. Instruct patients to swallow tablets whole; crushing, chewing, or dissolving can cause rapid release and absorption of a potentially fatal dose.,Accidental ingestion: Accidental ingestion of even one dose of Oxy Contin, especially by children, can result in a fatal overdose of oxycodone.,Neonatal opioid withdrawal syndrome: Prolonged use of Oxy Contin during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal in adults, may be life-threatening if not recognized and treated.,Risks from concomitant use with benzodiazepines or other CNS depressants: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate.
Central nervous system depression (e.g., dizziness, drowsiness, impaired coordination),Paradoxical reactions (e.g., increased nausea, vomiting),Risk of abuse and dependence due to psychoactive effects,Cardiovascular effects (e.g., tachycardia, hypotension),May cause seizures in patients with history of epilepsy,Not recommended for chemotherapy-induced nausea in patients receiving concomitant central nervous system depressants
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity (e.g., anaphylaxis) to oxycodone or any other components of the product
Hypersensitivity to dronabinol or any component of the formulation,History of hypersensitivity to marijuana or cannabinoids,Breastfeeding (due to potential infant exposure)
Avoid alcohol, which can increase oxycodone absorption and central nervous system depression. Grapefruit juice may alter oxycodone metabolism; limit or avoid consumption. No specific food restrictions, but high-fat meals may slow absorption slightly; take with or without food consistently.
High-fat meals may increase absorption; take consistently with respect to meals. Avoid grapefruit juice as it may increase dronabinol levels.
FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and oral clefts (1.5-fold) with opioid use, but confounded by underlying conditions. Second and third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS); maternal withdrawal may precipitate preterm labor. Avoid prolonged use near term due to risk of neonatal respiratory depression.
Dronabinol is a synthetic cannabinoid. Data on human pregnancy are limited. Animal studies show developmental toxicity at high doses. First trimester: potential risk of fetal abnormalities cannot be excluded; avoid unless benefit outweighs risk. Second and third trimesters: may cause fetal neurobehavioral effects; use only if clearly needed. Late pregnancy: associated with neonatal withdrawal symptoms and possible long-term neurodevelopmental effects.
Oxycodone is excreted into breast milk; relative infant dose is approximately 2.7–8.8% of maternal weight-adjusted dose. M/P ratio unknown. Monitor infant for sedation, respiratory depression, and poor feeding. American Academy of Pediatrics considers oxycodone compatible with breastfeeding with caution; avoid rapid accumulation in mothers with impaired metabolism (CYP2D6 poor metabolizers).
Dronabinol is excreted into breast milk. The milk-to-plasma ratio (M/P) is not established but cannabinoids are highly lipophilic and concentrate in milk. Effects on the nursing infant are unknown; however, potential for adverse effects on neurodevelopment exists. Breastfeeding is not recommended during dronabinol therapy.
Pregnancy increases oxycodone clearance by 1.3- to 2.5-fold due to enhanced hepatic metabolism (CYP3A4 and CYP2D6 induction) and increased renal blood flow. Dose adjustments may be necessary to maintain analgesia; clinical monitoring for pain control and withdrawal symptoms is essential. Titrate to effect; avoid abrupt discontinuation. Postpartum clearance returns to baseline over 1-2 weeks.
Pregnancy may alter dronabinol pharmacokinetics (increased volume of distribution, altered hepatic metabolism), but specific dose adjustments are not established. Use the lowest effective dose for the shortest duration. Monitor for increased adverse effects from altered metabolism. Avoid use in pregnancy unless potential benefit justifies potential risk to the fetus.
Oxy Contin is an extended-release formulation of oxycodone, indicated for around-the-clock pain management. Do not crush, chew, or break tablets, as this can lead to rapid release and fatal overdose. Use with caution in patients with respiratory compromise, head injury, or increased intracranial pressure. Monitor for signs of misuse, abuse, or addiction. Abrupt discontinuation may precipitate withdrawal; taper dose gradually. Constipation is common; consider prophylactic laxatives. Contraindicated in severe asthma, paralytic ileus, or hypersensitivity.
Dronabinol is synthetic THC, used for chemotherapy-induced nausea and vomiting (CINV) and appetite stimulation in AIDS wasting. Onset is 0.5-1 hour orally; titrate slowly due to psychoactive effects. May cause euphoria, dizziness, and cognitive impairment. Use with caution in patients with psychiatric disorders, seizure disorders, or history of substance abuse. Monitor for hypotension and tachycardia. Avoid concurrent use with other CNS depressants.
Take Oxy Contin exactly as prescribed, usually every 12 hours. Do not take more or less than directed.,Swallow the tablet whole with water. Do not crush, chew, or break the tablet, as this can cause a dangerous overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they increase the risk of severe sedation, respiratory depression, and death.,Do not stop taking Oxy Contin suddenly; ask your doctor how to safely discontinue the medication to avoid withdrawal symptoms.,Common side effects include constipation, nausea, drowsiness, and dizziness. Contact your doctor if you experience severe constipation, difficulty breathing, or signs of allergic reaction.,Store Oxy Contin in a secure place out of sight and reach of children and pets. Dispose of unused medication via a drug take-back program.,Do not drive or operate heavy machinery until you know how Oxy Contin affects you.,Inform all healthcare providers that you are taking Oxy Contin, especially before surgery or emergency treatment.
Take exactly as prescribed; do not increase dose or frequency.,Avoid driving or operating heavy machinery until you know how this medication affects you.,This drug may cause dizziness, drowsiness, or confusion; avoid alcohol and other CNS depressants.,Report any mood changes, hallucinations, or unusual thoughts to your healthcare provider.,Keep out of reach of children and store in a cool, dry place.,For nausea, take at least 1 hour before chemotherapy (if used as prophylaxis).,For appetite stimulation, take before meals.
No interactions on record
"Ethotoin, a hydantoin anticonvulsant, potentiates the central nervous system (CNS) depressant effects of dronabinol, a cannabinoid used for nausea and appetite stimulation. This additive CNS depression can lead to excessive sedation, dizziness, ataxia, and impaired cognitive and motor function. Clinically, patients may experience increased risk of falls, respiratory depression at high doses, and reduced ability to perform tasks requiring alertness."
"Nabilone, a synthetic cannabinoid agonist, and dronabinol, a synthetic delta-9-tetrahydrocannabinol, both exert central nervous system (CNS) depressant effects via activation of cannabinoid receptors (CB1) in the brain. Concurrent use leads to additive or synergistic CNS depression, resulting in enhanced sedation, dizziness, ataxia, and impairment of cognitive and motor function. Clinically, this may manifest as excessive drowsiness, confusion, or impaired coordination, increasing the risk of falls or accidents, especially in elderly or debilitated patients."
"Thiothixene, a typical antipsychotic with significant antidopaminergic and alpha-adrenergic blocking properties, may potentiate the central nervous system (CNS) depressant effects of dronabinol, a cannabinoid used for appetite stimulation and antiemesis. This additive CNS depression can lead to excessive sedation, dizziness, psychomotor impairment, and increased risk of falls or cognitive dysfunction. Clinically, patients may experience heightened somnolence, ataxia, or orthostatic hypotension, particularly during initiation or dose titration of either agent."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXYCONTIN vs DRONABINOL, answered by our medical review team.
OXYCONTIN is a Opioid Analgesic that works by Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression.. DRONABINOL is a Cannabinoid that works by Partial agonist at cannabinoid receptors CB1 and CB2; mimics endogenous cannabinoids, inhibiting adenylate cyclase and modulating neurotransmitter release (e.g., GABA, glutamate).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXYCONTIN and DRONABINOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXYCONTIN is: 10 mg orally every 12 hours; titrate based on pain severity and prior opioid exposure.. The standard adult dose of DRONABINOL is: 2.5-10 mg orally twice daily, titrated to effect; maximum 15 mg per day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXYCONTIN and DRONABINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXYCONTIN is classified as Category C. FDA Pregnancy Category C prior to 2020; no adequate studies in pregnant women. First trimester: Limited data suggest possible increased risk of neural tube defects (1.8-fold) and o. DRONABINOL is classified as Category D/X. Dronabinol is a synthetic cannabinoid. Data on human pregnancy are limited. Animal studies show developmental toxicity at high doses. First trimester: potential risk of fetal abnor. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.